liposomal curcumin

Phase 3Small molecule

SSignPath Pharma, Inc.

liposomal curcumin is one of 78 small molecule programs targeting Multiple Myeloma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaNot yet recruiting

HysterectomyNot yet recruiting

Multiple MyelomaPhase 1

Not yet recruiting

HysterectomyPhase 3

Not yet recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

47 2

Empliciti

Bristol-Myers Squibb

Phase 3

45 3

Ninlaro

Takeda

Phase 3

18 4

Keytruda

Merck & Co.

Phase 3

17 5

Biaxin

AbbVie

Phase 3

15 6

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 7

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23 8

Treanda

AAzurity Pharmaceuticals

Phase 3

19 9

Elranatamab

Cytosar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Multiple Myeloma

NCT07456605

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma

Not yet recruiting·UUniversity Health Network, Toronto·Phase 1·NCT07456605·20 enrolled

Lip1 trial

Evaluation of Liposomal Curcumin in Healthy Volunteers

Completed·SSignPath Pharma, Inc.·Phase 1·NCT01403545·50 enrolled

Hysterectomy1 trial

Effectiveness of Curcuminoids in Controlling Postoperative Pain Following Total Laparoscopic Hysterectomy

Not yet recruiting·EErzincan Military Hospital·Phase 4·NCT06886035·126 enrolled

Chronic Kidney Disease 5D1 trial

Examining the Impact of High-protein Oral Supplement With Liposomal Curcumin on Inflammation Markers and Oxidative Stress in Adults Undergoing Hemodialysis.

Completed·UUniversity of Florida·Phase 3·NCT06381076·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for liposomal curcumin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — liposomal curcumin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for liposomal curcumin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SignPath Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSignPath Pharma, Inc.

liposomal curcumin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Multiple Myeloma1 trial

Lip1 trial

Hysterectomy1 trial

Chronic Kidney Disease 5D1 trial

References

Drug Info

Quick Facts

Related News